Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from GlaxoSmithKline and Sanofi Genzyme.

Advances In™ Hematology: Assessing the Role of Monoclonal Antibodies for the Treatment of Multiple Myeloma

Release Date: May 29, 2020
Expiration Date: May 29, 2021

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of multiple myeloma, with a forward-looking perspective on how new and novel agents might impact clinical practice. The role of novel monoclonal antibody therapies in the treatment of multiple myeloma, including their mechanisms of action, efficacy data from recent clinical trials, adverse events associated with these drugs and their management strategies, as well as sequencing of drugs, will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.

Acknowledgement of Support

This activity is supported by educational grants from GlaxoSmithKline and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is directed toward oncologists and hematologists involved in the treatment and management of multiple myeloma. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals (HCPs) involved in the management of patients with multiple myeloma will also be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Integrate current and emerging options for the use of monoclonal antibodies in the treatment of MM into the treatment paradigm.
  • Optimize treatment sequencing for relapsed/refractory MM (R/R MM) based on patient risk stratification, prior lines of therapy, and other patient and disease characteristics.
  • Identify strategies to monitor for and mitigate adverse events associated with the use of monoclonal antibodies for patients with MM.
  • Evaluate emerging clinical trial data regarding the safety and efficacy of monoclonal antibodies used in the treatment of MM.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Saad Zafar Usmani, MD, FACP
Saad Zafar Usmani, MD, FACP
Chief, Plasma Cell Disorders Program
Director, Clinical Research in Hematologic Malignancies
Clinical Professor, Medicine
UNC-Chapel Hill School of Medicine
Chapel Hill, NC

Disclosures: Grant/Research Support: Amgen, Array BioPharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda; Consultant: Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, SkylineDx, Takeda,; Speakers Bureau: Amgen, Celgene, Janssen, Sanofi, Takeda.

Thomas G. Martin, MD
Thomas G. Martin, MD
Interim Chief, Hematology
Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program
Codirector, Myeloma Program
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant/Research Support: Amgen, Sanofi, Seattle Genetics; Consultant: Juno Therapeutics, Roche.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By